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A B S T R A C T
Glomerulonephritis (GN) refers to a group of renal diseases aﬀecting the glomeruli due to the damage mediated
by immunological mechanisms. A large proportion of the disease manifestations are caused by disturbances in
the complement system. They can be due to genetic errors, autoimmunity, microbes or abnormal im-
munoglobulins, like modiﬁed IgA or paraproteins. The common denominator in most of the problems is an
overactive or misdirected alternative pathway complement activation. An assessment of kidney function,
amount of proteinuria and hematuria are crucial elements to evaluate, when glomerulonephritis is suspected.
However, the cornerstones of the diagnoses are renal biopsy and careful examination of the complement ab-
normality. Diﬀerential diagnostics between the various forms of GN is not possible based on clinical features, as
they may vary greatly. This review describes the known mechanisms of complement dysfunction leading to
diﬀerent forms of primary GN (like IgA glomerulonephritis, dense deposit disease, C3 glomerulonephritis, post-
infectious GN, membranous GN) and diﬀerences to atypical hemolytic uremic syndrome. It also covers the basic
elements of etiology-directed therapy and prognosis of the most common forms of GN. Common principles in the
management of GN include treatment of hypertension and reduction of proteinuria, some require im-
munomodulating treatment. Complement inhibition is an emerging treatment option. A thorough understanding
of the basic disease mechanism and a careful follow-up are needed for optimal therapy.
1. Introduction
Complement activation and its regulation have been considered as
complex phenomena. This has possibly delayed the general under-
standing of the complement system as a direct primary cause or as the
main eﬀector mechanism for kidney injury. In this review we will de-
scribe diﬀerent forms of primary GN, where complement is involved.
Usually the complement attack inﬂuences the function of the glomeruli.
The glomerulus is an essential part of the nephron. Primary urine is
ﬁltered through the glomerulus and continues to the tubule, where
reabsorption of urine components occurs. If renal disease is mainly
aﬀecting glomeruli, it is called glomerulonephritis. The targets in glo-
meruli include capillary endothelial cells, basement membrane, me-
sangial cells and the podocytes with their foot processes. Vast damage
in glomeruli eventually aﬀects the other parts of the nephron and in
end-stage renal disease (ESRD) it may be impossible to deﬁne the origin
of the disease [1]. Some glomerulonephritides may damage only some
glomeruli (focal damage), others may aﬀect all glomeruli (diﬀuse da-
mage). Global damage destroys the whole glomerulus, whereas seg-
mental injury aﬀects only parts of the glomerulus [2]. The nomen-
clature of diﬀerent forms of GN is often taken directly from the
histological description. Light microscopy (LM) in combination with
immunoﬂuorescence (IF) microscopy forms the basics of diﬀerential
diagnostics, and electron microscopy (EM) has traditionally been con-
sidered to complete the ﬁnal diagnosis [3]. For every patient com-
mencing renal replacement therapy due to glomerulonephritis there are
about 11 subjects with biopsy-proven glomerulonephritis [4]. In gen-
eral, glomerulonephritides cause approximately 20% of the total
burden of chronic kidney disease [1].
Glomerulonephritis can be caused by many diﬀerent factors. In most
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cases, however, the damage is immune-mediated with a variable impact
from genetic and environmental factors [5]. Primary glomerulone-
phritides are diseases limited to kidneys, but glomerular damage can
also be part of a systemic illness, like vasculitis or systemic lupus er-
ythematosus. In the latter, circulating antigen-antibody or DNA-histone
complexes and their accumulation into vascular walls are believed to be
a central mechanism.
The diagnosis of glomerulonephritis requires kidney biopsy, and it is
not possible to recognize various glomerulonephritides solely on the
basis of clinical features. However, common clinical features in all of
them are hypertension combined with hematuria and variable amount
of proteinuria and either normal or deranged renal function [1]. All
glomerulonephritides share also the same prognostic features. Con-
tinuous heavy proteinuria, renal insuﬃciency and hypertension are
independent markers of a progressive loss of the renal function. Also, a
vast chronic damage in renal biopsy predicts a faster loss of renal
function [1].
The treatment of glomerulonephritis depends highly on the clinical
picture. Common principles in the management include treatment of
hypertension and reduction of proteinuria. Some forms of glomer-
ulonephritis require immunomodulating treatment [3]. The indications
for immunomodulating treatment vary according to the disease and
clinical scenario [1]. In rapidly progressive glomerulonephritis it is vital
to commence eﬃcient immunosuppressive treatment at an early phase
of the disease in order to preserve renal function [6]. In slowly pro-
gressive diseases immunosuppressive treatment may not be indicated at
all. Complement inhibition is an emerging treatment option, since in
many forms of glomerulonephritis complement activation is the central
mechanism causing glomerular injury. However, currently the use of
complement inhibition in glomerulonephritis, unlike in atypical he-
molytic uremic syndrome (aHUS), is oﬀ-label.
2. IgA glomerulonephritis
IgA glomerulonephritis (IgAN) (synonyms IgA nephropathy or
Berger’s disease) is the most common primary glomerulonephritis with
marked diﬀerences worldwide. The annual incidence ranges between
0.2–5.7/100 000 [7]. Men are more often aﬀected, and the usual age of
diagnosis is between 20–40 years, although the disease can manifest at
any age [8].
The detailed etiology of IgAN is still unresolved. The patients have
several derangements in the IgA immunoglobulins, but that alone is not
suﬃcient to cause the disease [9]. A multi-hit model has been sug-
gested, where the initiating event is the formation of galactose-deﬁcient
IgA1 in genetically predisposed patients leading to the production of
autoantibodies, formation of circulating immune complexes and ﬁnally
renal deposition and injury [10]. Compared to normal IgA, a proportion
of the circulating and kidney deposited IgA1 in IgAN has altered
characteristics, probably due to abnormal glycosylation and/or dimer-
ization. The altered IgA could thereby originate from mucosal surfaces
and, being in the “wrong” place, activate the alternative or lectin
pathways of complement [11]. Contributing factors could include mi-
crobial infections, especially on mucosal surfaces, food antigens or yet
unknown other environmental factors. IgA1 immunoglobulin binding
to its antigens could lead to the formation of immune complexes and
eventually their accumulation in the glomeruli causing the clinically
evident disease [12]. Most cases are sporadic, but familial aggregation
has been described in less than 15% of the cases [13]. Healthy relatives
often have the same derangements in the IgA immunoglobulin system
as the patients. This strongly suggests that additional factors in the
pathogenetic process are needed [14,15].
The diagnosis of IgAN is based on IF microscopy, where IgA is the
predominant deposited protein in the mesangial areas. The LM ﬁndings
can be variable. Also, immunoglobulins other than IgA may be present
in the glomeruli, and about 90% of the patients have C3 deposits in-
dicating complement activation in the glomeruli [8,16]. Autopsy and
histological studies have implied that C3 co-deposits may distinguish
isolated IgA from nephritogenic IgA deposition, as the majority of pa-
tients with only IgA staining, but without any clinical renal disease, do
not usually have C3 co-deposition [10,17,18]. In more comprehensive
studies also other complement components have been detected in the
glomeruli: C4d, mannose-binding lectin (MBL), L-ﬁcolin, MBL-asso-
ciated serine proteases 1, 2, and 3, properdin, factor H, factor H-related
proteins (FHR1 and FHR5) and the membrane-attack complex (MAC)
[19].
Hypocomplementemia is not a typical feature of IgAN, but some
researchers have found high serum C3/IgA ratios, especially in com-
bination with glomerular C3 staining and high serum C4b binding
protein levels, to be indicative of a worse outcome [20–22]. Also, low
circulating MASP-3 level has been associated with progressive IgAN
along with increased glomerular staining of FHR5 [23]. Among the
genomic loci associated with susceptibility of IgAN, the locus on
chromosome 1q32 includes a cluster of genes that encode factor H-re-
lated proteins. This cluster is associated with a risk of developing IgAN
[10]. Based on published data, it can be concluded that activation of
complement plays a role both in the pathogenesis and as a prognostic
marker in IgAN. Activation seems to be mediated by alternative and
lectin pathways and happens both in circulation and locally in the
glomeruli [19,24,25].
The most typical clinical picture of IgAN is that of fortuitously found
hematuria and proteinuria in combination with hypertension. Less than
half of the patients have temporary macroscopic hematuria during
acute illness. The minority has either acute bouts of massive proteinuria
resembling minimal change glomerulonephritis or rapidly progressive
glomerulonephritis resembling vasculitis [15,26]. Henoch-Schönlein
purpura, or preferably IgA vasculitis, is a systemic form of IgAN with
purpura, arthralgias/arthritis and gastrointestinal symptoms (enteritis,
pain) [27]. It is caused by small vessel vasculitis with typical IgA-
dominant immune deposits in aﬀected organs. Renal histology is
identical with primary IgAN. The systemic disease is clearly more
common in children, but can manifest in adulthood, as well [24]. The
treatment of IgAN follows mostly the same guidelines as that in the
primary disease [24]. IgAN has been reported to be linked with various
other diseases (celiac disease, liver diseases, inﬂammatory bowel dis-
eases and connective tissue diseases) more than one would expect
merely based on coincidence. Causality is not always clear, and optimal
treatment of secondary IgAN depends on the clinical scenario. Most
reports suggest addressing the underlying disease with additional sup-
portive measures for chronic kidney disease [28].
No curative treatment for IgAN is available at the moment, but a
minority of the patients may undergo complete remission even without
any treatment [29]. The cornerstone of the treatment is strict control of
hypertension with antiproteinuric compounds (mainly renin-angio-
tensin blockers). Antiproteinuric treatment is indicated even in nor-
motensive patients [3]. For selected patients a 6-month course of cor-
ticosteroids can be oﬀered, if renal function is still good enough
(eGFR>30ml/min), and the amount of proteinuria continues at an
unacceptable level [3,24,26]. Several complement inhibiting drugs are
currently being evaluated in clinical studies, but none of them is oﬃ-
cially indicated for the treatment yet [30]. Oxford classiﬁcation of
histology may be guiding the treatment decisions [31], as well as a
recently published prediction tool [32]. In cases resembling minimal
change glomerulonephritis or rapidly progressive glomerulonephritis
the treatment follows their guidelines [26]. Most patients have slowly
progressive disease and ESRD develops in some 20–40 % of the patients
within 20 years after diagnosis [24]. IgAN can also recur in renal
transplants in some 50% of the cases. The rate of recurrence was found
to be higher in studies, where protocol biopsies were performed than
when biopsies were done for clinical reasons only [33].
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3. Membranoproliferative glomerulonephritis (Ig-MPGN, DDD,
C3GN)
Membranoproliferative glomerulonephritis (MPGN) (synonym me-
sangiocapillary glomerulonephritis) accounts for approximately 7–10%
of all biopsy conﬁrmed cases of glomerulonephritis (34, 35). Its annual
incidence has been reported to be 0.14-0.93 /100 000. The incidence
has been decreasing due to a lower occurrence of viral and bacterial
infections that may cause the disease due to chronic antigenemia [7].
MPGN is mainly diagnosed in childhood or adolescence, but may occur
at any age [36].
Understanding of the pathophysiology of MPGN has greatly ad-
vanced in the past 10 years. Recently, a new classiﬁcation into two
forms, immune complex-mediated MPGN (Ig-MPGN) and complement-
mediated MPGN (C-MPGN) or C3 glomerulopathy (C3G) has been in-
troduced [37,38]. It reﬂects progress in the research of the disease
pathophysiology and has led to a better understanding of the under-
lying distinct causes. Ig-MPGN is caused by increased amounts of cir-
culating immune complexes due to chronic antigenemia (chronic in-
fections, autoimmune diseases, malignancies, plasma cell dyscrasias or
other persistent antigen stimuli) leading to the activation of the clas-
sical pathway of complement. The evaluation should therefore focus on
identifying the trigger driving the chronic antigenemia. If no trigger can
be found, and the rare cases of C3G have been excluded, the disease is
labeled as idiopathic Ig-MPGN [39].
C3G occurs because of dysregulation of the alternative complement
pathway [40]. Known and potential underlying causes are described in
Fig. 1 and their points of action in the complement cascade in Fig. 2.
Dysregulation can be due to mutations in the complement proteins or to
autoantibodies that promote complement activation [34]. In addition, a
signiﬁcant proportion of cases have been found to be due to monoclonal
immunoglobulins (paraproteins) [41,42].
C3G is subclassiﬁed into dense deposit disease (DDD) and C3 glo-
merulonephritis (C3GN) based on the presence or absence, respectively,
of dense glomerular basement membrane deposits by EM [34,43]. The
dense deposits contain mostly an abundance of the C3b protein and
factors of the terminal pathway. C3b is derived from a large-scale ac-
tivation of ﬂuid phase C3 that also leads to notably low levels of plasma
C3 [44]. A speciﬁc genetic mutation or autoantibody can be found in a
signiﬁcant proportion of patients, but in many patients no clearly
identiﬁable cause can be detected. In one study with 73 C3G patients,
18% had a likely pathogenic genetic variation [45]. Autoantibodies to
the alternative pathway C3 convertase, C3bBb, are called C3 nephritic
factors (C3Nef). They stabilize the C3bBb complex to increase its ac-
tivity and prolong its half-life similarly as properdin. C3Nef activity is
noted in approximately 80–90% of DDD patients and 40–60% of the
C3GN patients [45,46]. C3Nef is found more commonly in younger
patients. As many of the commonly used diagnostic methods do not
directly show the nature of the C3 activating factor as an IgG class
autoantibody, it is possible that other factors contribute, as well. In
more than one half of patients, serum C3Nef persists throughout the
disease course [47]. C3Nef is associated with clinical evidence of
complement activation, such as a decrease in CH50, a reduction in
plasma C3 and an increase in C3 activation products. However, no clear
relationship between C3Nef, plasma C3 levels and disease prognosis has
always been detected [47]. Another nephritic factor has been char-
acterized by the ability to stabilize the C5 convertase of the alternative
pathway (C5Nef). This factor seems to require properdin (P), a known
positive regulator of the alternative pathway. In addition, auto-
antibodies against the C3 convertase of the classical and lectin path-
ways (C4Nef) have been described [48]. These autoantibodies have
been associated with both Ig-MPGN and C3G. Factor H autoantibodies
can be detected in approximately 11% of C3G patients [49]. In some
patients with DDD inherited mutations in factor H have been detected.
The mutations either cause a deﬁciency of factor H or are located in the
N-terminal part of factor H, which is needed for its regulatory activity
[40,50].
When C3G is diagnosed, full evaluation of the complement system is
recommended [50]. This includes a mutation panel analysis and de-
termination of the nature of the complement activating factor or dys-
function in the patient blood. If no secondary cause in Ig-MPGN is
found, screening similar to C3G is recommended. It has been shown
that a defective control of the complement alternative pathway can be
found in about 20% of Ig-MPGN patients [51,52]. Paraproteins can also
cause either Ig-MPGN or C3G. In the latter case the paraprotein could
act as a functional inhibitor of the complement regulating protein factor
H, as we have initially described [44,53]. In this speciﬁc case mono-
clonal immunoglobulin lambda light chains bound directly to the third
domain of factor H blocking its functional activity (binding to C3b,
cofactor activity for C3b inactivation and decay accelerating activity).
This “miniautoantibody”, composed of two light chains only, led to
massive complement activation and plasma C3 consumption in the
patient. Some paraproteins have been found to have a C3Nef activity,
but in many cases, however, the exact mechanisms of the paraproteins
in causing complement activation and C3G have remained unknown
[54].
MPGN denotes glomerular changes characterized by mesangial ex-
pansion and hypercellularity and by thickening of the glomerular ca-
pillary wall. Eventually this leads to characteristic features with double
contours in the basement membrane [55]. IF microscopy reveals bright
staining for C3. For the diagnosis of C3G the intensity of C3 staining has
somewhat arbitrarily been determined to be at least two orders of
magnitude greater than that for any other immunoreactant, like IgG
[50]. More dominant staining for immunoglobulins is characteristic for
Ig-MPGN [56]. EM shows that deposits occur in the mesangial areas as
well as in the subendothelial and subepithelial spaces in Ig-MPGN and
C3GN, whereas in DDD they occur intramembranously and mesangially
[55]. It is of note that only 71% of C3G cases have an MPGN pattern in
LM [51]. In most of the other cases, the pattern shows mesangial pro-
liferation without capillary wall changes [55]. Large hump-shaped
subepithelial deposits may be seen in C3G [42]. MPGN can also be
found in the absence of immune complexes or complement deposits on
IF. Then thrombotic microangiopathy (TMA) should be considered
[34,35,55]. Curiously, in the case of paraprotein-associated C3GN the
paraproteins can be masked and may be not be directly visible by IF
microscopy. They can be revealed by protease treatment of the kidney
sections [57]. However, since complement activation in C3G often takes
place in the ﬂuid phase, one does not need to expect deposition of the
paraproteins in the kidney glomeruli.
Fig. 1. C3 glomerulopathy has multiple causes. These include genetic muta-
tions or autoantibodies. Also paraproteins (immunoglobulin M-components)
and infectious agents can lead to C3G. FHR, factor H-related proteins; GAS,
group A streptococcus; EBV, Epstein-Barr virus; mIgG, monoclonal im-
munoglobulins.
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The clinical presentation of MPGN at diagnosis varies from
asymptomatic hematuria and proteinuria to a more severe disease with
nephrotic or nephritic syndrome or even a rapidly progressive glo-
merulonephritis [34]. Half of the patients have a full-blown nephrotic
syndrome, while the rest either have a nephritic syndrome or no
symptoms [36]. Some may also have periodic macroscopic hematuria.
A third of the patients are hypertensive and even more so in progressive
disease. Renal insuﬃciency is evident in half of the patients. MPGN can
sometimes go into spontaneous remission, and ﬂuctuations in the
clinical picture are not uncommon [36]. All MPGN types have some
level of hypocomplementemia, but this can also be periodic [52,58].
Individuals with C3G, especially with DDD, may develop drusen lesions
in the eye as a result of an inability to remove eye pigment and mis-
directed complement activation, often in early adulthood [50,59]. The
long-term risk for visual problems in individuals with C3G is approxi-
mately 10%. No apparent correlation, however, exists between disease
severity in the kidney and in the eye [59]. Also acquired partial lipo-
dystrophy (PLD) may develop as a direct aftermath of complement
activation in 5–17% of persons with C3G [50,59].
PLD is a rare disease, characterized mainly by symmetrical loss of
subcutaneous fat from the upper part of the body [60]. Apart from its
linkage to DDD, PLD can be caused e.g. by an acute viral infection,
diabetes mellitus, liver dysfunction, pancreatitis or systemic auto-
immune diseases. Most patients with DDD-associated PLD have hypo-
complementemia [61]. The C3Nef autoantibodies lead to hypercata-
bolism of C3 via the alternative pathway by stabilizing the activity of
the C3bBb enzyme [62]. It is assumed that the loss of fat is due to a
direct complement-mediated damage to adipocytes. Adipocytes play an
important role in promoting complement attack, because they are the
principal producers of factor D (adipsin), the speciﬁc key enzyme ac-
tivating factor B, which is needed for the assembly of the C3 convertase
of the alternative pathway [63].
The treatment of MPGN depends on the etiology, and has not been
well established. No single treatment has been proven to be ideal in
C3G. Eﬀective treatment of hypertension and proteinuria, particularly
via renin-angiotensin-aldosterone system (RAAS) blockade, is re-
commended, as these treatments slow progression of all proteinuric
chronic glomerular diseases. Aliskiren (direct renin inhibitor) has
shown positive results in three patients with DDD demonstrating de-
creased systemic and renal complement activation [64].
If in Ig-MPGN an underlying condition is found, the treatment needs
to address this primary cause [34]. If no underlying cause can be found,
treatment aimed at reducing blood pressure and proteinuria may be
suﬃcient. For more severe cases, immunosuppressive therapy is re-
commended, although the evidence of using these agents has been
collected from trials prior to the novel classiﬁcation system [35]. Be-
cause of its rarity and possibly also because of heterogeneity, there are
only a limited number of studies addressing the treatment of C3G.
Plasma infusions or exchange may be beneﬁcial to restore the depleted
plasma factor levels if the patient has been diagnosed with a comple-
ment protein deﬁciency or abnormality. If circulating autoantibodies
that disturb complement regulation can be found, plasma exchange (or
immunoadsorption of the antibodies) may be helpful [50,65]. Un-
fortunately, unless speciﬁcally addressed (e.g. by rituximab) the auto-
antibody production continues and the antibodies return back to the
circulation. Also, despite the documented removal of C3Nefs, a fa-
vourable outcome may not be achieved solely by plasmapheresis [66].
It seems to be eﬃcacious in factor H autoantibody-associated DDD.
Immunosuppressive medication is often given either with or without
plasma exchanges, but with variable results [67]. A recent study sug-
gested that mycophenolate mofetil (MMF)-based immunosuppressive
therapy combined with corticosteroids is beneﬁcial in patients with
C3GN and can decrease the rate of progression to end-stage kidney
failure for reasons that are not completely clear [68]. Further studies
are needed to tailor optimal therapies for clearly deﬁned subgroups of
patients. It is diﬃcult to select the right therapy regimen without un-
derstanding the basic pathogenetic mechanism underlying the disease.
The second speciﬁc complement inhibitor, after C1 inhibitor for
hereditary angioedema, currently available for clinical use is eculi-
zumab, a humanized antibody against C5. It prevents C5 cleavage and
generation of C5a and membrane attack complex (MAC) [69]. How-
ever, while eculizumab is eﬀective in preventing the generation of C5a
and MAC, it is unlikely to be useful, if the majority of renal damage is
mediated by C3 hypercatabolism [70]. Its eﬀectiveness has been re-
ported in small case series and single patient reports with roughly 60%
of the patients beneﬁting from the treatment [71]. The usefulness of
eculizumab may be predicted by analyzing the activation proﬁle of C3/
C5Nef in C3G patients [71]. Soluble CR1 therapy in a murine model of
human C3GN stopped alternative pathway activation resulting in nor-
malization of serum C3 levels and clearance of its activation products
from glomerular basement membranes [72]. The C3 inhibiting comp-
statin analog Cp40 prevented complement-mediated lysis of sheep er-
ythrocytes in sera from C3G patients in vitro [73], but its pharmaco-
kinetic properties are not optimal for treatment of C3G. Nevertheless,
Fig. 2. Points of action of the diﬀerent potential causative factors of C3G in the complement cascade. FHR, factor H-related proteins; C3/C5Nef, C3/C5 nephritic
factor.
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rational treatment of C3G should, however, involve inhibition of C3
activation, e.g. by blocking the activity of factor D. A number of drugs
that are in pre-clinical development may allow a more targeted therapy
in the future [55]. It is, however, important to note the increased
therapy-related risk for infections, when complement activity is sup-
pressed.
MPGN has a progressive nature in the majority of cases. Within 10
years of diagnosis, about 40% of patients result in an ESRD and MPGN
often recurs in kidney transplants leading to subsequent renal failure
and restart of dialysis [34]. With DDD, the recurrence rate is about
80–90% and half of the grafts are lost due to the recurrence within 5
years [34,35].
4. Mechanisms underlying the development of C3GN
While the causes and mechanisms for DDD are relative well un-
derstood, those for C3GN are less well deﬁned. The overall outcome in
C3GN is prolonged and extensive C3 activation and C3b deposition in
the glomeruli, but not in the same extent and homogenous manner as in
DDD, where C3b deposition leads to dense intramembranous deposits
[40]. It is apparent that C3GN can be caused by multiple factors
(Fig. 1). Paraproteins occur in about one third of cases, more so in el-
derly patients [74,75]. In some cases, they have been shown to have
direct factor H blocking or C3 nephritic factor activity. Otherwise, they
seem to promote complement activation in the ﬂuid phase and activate
C3 during a prolonged time course. Whether they become deposited in
situ in the kidney glomeruli and activate complement locally in situ is
not clearly known. Also, their possible tissue damaging role in other
organs has not been much studied yet. Paraproteins could cause amy-
loidosis, proliferative or ﬁbrillary glomerulonephritis, immunotactoid
glomerulopathy or cryoglobulinemia, but none of these forms have
been described in the context of C3GN.
Genetic alterations constitute a heterogeneous group of causes for
C3GN. Factor H-related proteins comprise a group of ﬁve plasma pro-
teins: FHR1, FHR2, FHR3, FHR4 and FHR5 (76; Cserhalmi et al, this
issue). They are all encoded in the Regulators of Complement
Activation (RCA) gene cluster on chromosome 1 [77]. Because of in-
ternal homologies in the large number of sequences for individual do-
mains (called complement control protein repeats, CCPs) this gene re-
gion is unstable. This can lead to genetic alterations, like deletions,
duplications or hybrid genes [78–80]. The products or consequences of
these alterations can have functional consequences that lead to the
development of C3GN or to atypical haemolytic uremic syndrome
(aHUS).
Each member of the FHR protein group can bind to the C3d region
of C3b but, with the possible exception of FHR5, they lack their own
direct complement inhibitory function. The 2 most C-terminal domains
of the FHR proteins are homologous to those of factor H [76]. These
domains contain the C3d as well as in some cases also the surface
polyanion binding sites. In the N-terminus, instead, the FHR proteins
have domains that can mediate homo- or heterodimerization [81]. The
properties of FHRs suggest that they could act as competitors for factor
H in binding to C3b/d-coated surfaces. They could bind to both C3d and
the polyanions and inhibit factor H binding. This ability could be en-
hanced by their ability to assemble into dimers, which - because of
multivalent binding - would have a higher avidity than factor H. In
other words, the FHRs could thus control the regulatory activity of
factor H and in fact promote complement activation ([81,82]; see also
Cserhalmi et al in this issue).
In C3GN patients a number of diﬀerent genetic variants of the FH/
FHR family of proteins have been observed [40]. These include, for
example, proteins containing duplicated parts of FHR1 or FHR5 and
FHR3-1, FHR2-5, FHR5-2 and FHR1-5 hybrid proteins (summarized in
83). Naturally, these abnormal proteins would have the ability to dis-
turb factor H-mediated regulation of complement activation and
thereby cause C3GN or DDD. In some rare cases, also mutations in C3 or
factor B can lead to an overactive C3 convertase.
While distinct autoantibodies, like anti-H or C3Nef, or paraproteins
have been discovered in patients with C3GN, the reasons for the
emergence of these complement activation promoting factors is still a
mystery. Paraproteins are monoclonal immunoglobulins produced by B
cells or B cell-derived plasma cells. It is possible that they arise as an
accidental occurrence of a B or plasma cell clone, whose product would
be an immunoglobulin with an ability to cluster or polymerize in cir-
culation or in kidney glomeruli. Some could have C3/C5Nef activity.
While this could be the consequence of a spontaneous error in the
immunoglobulin gene rearrangement or hypermutation process, also an
underlying infection e.g. by the B cell-tropic Epstein-Barr virus could be
the initial stimulating factor. Some paraproteins represent products of
malignant multiple myelomas, which require speciﬁc treatment.
For the development of C3Nef or antibodies against factor H no root
causes are known at the moment. Theoretically, an underlying infection
by microbes that assemble C3bBb on their surfaces or carry factor H
binding proteins could be envisaged to initiate autoantibody formation.
Acquisition of complexes with foreign proteins into self-reactive B cells
could accidentally lead to immunization against self-proteins, as well, if
the foreign partner leads to activation of helper T cells. A homozygotic
deﬁciency of the FHR3-1 gene region in the RCA cluster is known to
predispose to the development of factor H autoantibodies [84,85]. This
suggests that FHR1 (and/or, less likely FHR3) is needed for the main-
tenance of tolerance to factor H. A conformational change in factor H,
mimicking that of FHR1, upon binding to microbial factor H binding
proteins could thus induce autoantibody formation in a situation, where
the person lacks FHR1 and therefore is not tolerant to it [86]. The anti-
H autoantibodies are restricted in their characteristics, e.g. by main-
taining their avidity, target speciﬁcity and often having only kappa or
lambda light chains, and they also remain relatively constant in in-
dividual patients [87]. It is apparent that a mutation or an autoantibody
alone would not usually be enough to cause C3GN. Precipitating factors
are needed. For this, infections would also be a natural factor, that
amplify complement activation and could initiate the process leading to
C3GN.
5. Post-infectious glomerulonephritis
Post-infectious glomerulonephritis (PIGN) is a self-limiting glo-
merulonephritis that most commonly develops as a consequence of
group A streptococcal infection, but can develop after other infections,
as well [55,88]. Streptococcus pneumoniae is another bacterial pathogen,
which could be involved in PIGN. Some pneumococcal strains produce
neuraminidase enzyme that could sensitize glomerular structures, en-
dothelial cells or immunoglobulins to complement attack. Sialic acids
are well known to protect our own cell surfaces from complement at-
tack.
Due to eﬀective treatment of infections PIGN has become increas-
ingly rare in Western countries [89]. The disease is uncommon in
adults. PIGN predominantly manifests as a diﬀuse endocapillary glo-
merulonephritis [55]. Codeposition of IgG and C3 is commonly ob-
served, while C3-dominant glomerular deposition is also observed [88].
Subepithelial humps are often seen on EM [88,89].
The clinical presentation of hematuria, less than nephrotic protei-
nuria and low C3 levels are typical [90]. C3-dominant glomerular de-
position was previously considered to represent a later stage of PIGN.
However, the emergence of C3GN as a distinct entity has led to re-
assessment of this concept [88]. There have been reports where the
initial presentation was PIGN, but the patients later developed chronic
C3GN [91–94]. Therefore, in any patient with a C3-dominant PIGN,
persistent clinical abnormalities, including hypocomplementemia,
proteinuria or declining renal function, should lead to further in-
vestigation of the alternative pathway of complement [38,88]. As PIGN
patients usually have low levels of circulating C3, one might even
postulate that PIGN could be considered as a self-limiting form of C3G,
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and that PIGN and C3G form a diseases spectrum rather than two
completely distinct diseases [55,91]. Accordingly, reassessment of his-
torical PIGN cases has led to reclassiﬁcation as C3G in 25% of the cases
[91].
As by deﬁnition PIGN is self-limited, supportive therapy is sug-
gested, although even dialysis may be needed temporarily. In most
severe cases, corticosteroids have also been given [88]. The clinical
ﬁndings typically resolve within weeks, but complete resolution may
take up to 6 months [88].
6. Membranous glomerulonephritis
Membranous glomerulonephritis (MGN) (synonym membranous
nephropathy) is one of the most commonly encountered reason for
adult nephrotic syndrome being twice as common in males than fe-
males. Annual incidence of 1.2/100 000 has been reported [7,95]. In
children MGN is extremely rare. The usual age of onset is 50–60 years
of age [96].
The MGN disease is caused by circulating autoantibodies that bind
to an autoantigen on the surface of the podocytes. IgG immune com-
plexes aggregate in the subepithelial space disturbing the normal bar-
rier function of basement membrane. The most common target antigen
is the podocyte protein M-type phospholipase A2 receptor (PLA2R)
[97]. In total, 70–80% of patients with primary MGN have detectable
anti-PLA2R antibodies [97], and 3–5% have detectable anti-throm-
bospondin type-1 domain-containing protein 7A (THSD7A), a second
target antigen identiﬁed in 2014 [98]. Anti-PLA2R antibodies are
highly speciﬁc for primary MGN and are not found in other forms of
glomerulonephritis or in secondary MGN. It has even been suggested
that in the presence of anti-PLA2R antibodies, kidney biopsy is not
necessary, unless there is a suspicion of another disease [3]. In ap-
proximately 20% of cases in adults, the MGN lesion is secondary to
various disorders, including chronic infections, systemic and auto-
immune diseases, drugs and malignancy [99].
Light microscopy in MGN shows thickening of the glomerular ca-
pillary wall because of subepithelial deposition of immune complexes
and complement components and new basement membrane synthesis.
Within the basement membrane characteristic spikes are visible [99].
Immunoﬂuorescence analysis reveals staining for IgG, which is nearly
always accompanied by C3 [100] and also PLA2R-antibodies in the
primary form of the disease [99]. Electron microscopy shows sub-
epithelial deposits [99]. Subepithelial, intramembranous and mesangial
deposits suggest secondary MGN, an exclusively subepithelial location
of the deposits is more typical for primary MGN. IgG subclass staining
may further help in classiﬁcation. IgG1, IgG2 and IgG3 generally
dominate in the deposits of secondary MGN, whereas a preponderance
of IgG4 is characteristic for primary MGN [99,100]. C1q is typically
absent in primary MGN, but C4d is found in subepithelial deposits
[100]. The mannose-binding lectin (MBL) pathway has recently
emerged as a potential explanation to account for the presence of glo-
merular C4 in primary MGN [100]. Although serum levels of comple-
ment proteins are usually normal in primary MGN, increases in C3a and
C5a levels indicated activation of complement and correlation with
anti-PLA2R antibody levels in a recent Chinese study [101]. It was
postulated that complement may be activated through the lectin
pathway in patients with anti-PLA2R antibodies, and through the al-
ternative pathway in patients without anti-PLA2R antibodies [101].
MGN commonly presents as nephrotic syndrome, but approximately
20% of patients with MGN present with non-nephrotic proteinuria
[100]. Patients should be treated with supportive care from the time of
diagnosis to minimize protein excretion. Patients with primary MGN
and proteinuria> 3.5 g/d at diagnosis, and those who fail to reduce
proteinuria to< 3.5 g after 6 months of supportive care or have com-
plications of nephrotic syndrome, should be considered for im-
munosuppressive therapy [96]. A serology-based rather than protei-
nuria-based approach has also been suggested [99]. Levels of anti-
PLA2R antibodies and possibly, anti-THSD7A antibodies tightly corre-
late with disease activity [99]. In secondary MGN the treatment is
usually dictated by the underlying cause.
As many as one third of patients with MGN have a progressive loss
of kidney function and may progress to ESRD at a median of 5 years
after diagnosis. The disease can recur in kidney transplants [100].
7. Hemolytic uremic syndrome
Hemolytic Uremic Syndrome (HUS) is an entity distinct from glo-
merulonephritis, yet it is important to keep in mind for diﬀerential
diagnostic purposes, and because it also is a systemic disorder and can
have a severe disease course [102]. HUS is a renal thrombotic micro-
angiopathy characterized by a triad of symptoms; (i) microangiopathic
hemolytic anemia, which means damage to red blood cells as they pass
through the narrow microvasculature, (ii) thrombocytopenia, i.e. de-
creased levels of platelets due to the extensive formation of thrombi,
and (iii) microvascular glomerular thrombosis, formation of blood clots
in the kidneys, which can lead to acute renal failure [103,104]. HUS
can be typical or atypical. Typical HUS is caused by Shiga- or Shiga-like
toxins, which can be produced by enterohemorrhagic E. coli (EHEC) or
Shigella bacteria. This form of disease is usually self-limiting, although it
can be severe and lead to kidney failure and other severe complications.
The causative bacteria also cause diarrhea, sometimes bloody diarrhea,
and aﬀect predominantly kidney glomeruli. The atypical form of HUS
involves usually the renal and interlobular arteries and is not self-lim-
iting. The atypical form can be sporadic or familial, whereas the typical
form is only sporadic [105]. aHUS and HUS also need to be separated
from other forms of thrombotic microangiopathies, like thrombotic
thrombocytopenic purpura (TTP), where complement has not been
shown to be directly involved. Some hints for diﬀerential diagnostics
are provided in Table 1.
The most common cause for atypical HUS (aHUS) is genetic. It can
be caused by mutations that were ﬁrst found in factor H [106], and later
in the other complement regulators, factor I or membrane cofactor
protein (MCP; CD46) or in thrombomodulin, which is an inhibitor of
both complement and the coagulation cascade (reviewed by Nester
et al; 107). In addition, mutations in C3 and factor B that increase the
activity of the C3 convertase, C3bBb, on surfaces can lead to aHUS.
aHUS-related mutations in factor H are usually located in its C-terminal
domains 19 and 20 that contain binding sites for the C3d domain of C3b
and for negatively charged surface polyanions, notably for sialic acids,
like gangliosides on endothelial cells [108–110]. Autoantibodies
against the same C-terminal region of factor H cause approximately
12% of aHUS [111]. As factor H is an inhibitor of complement, the
presence of these autoantibodies leads to a targeted complement attack
against self-surfaces, vascular endothelia and blood cells, because of
decreased local regulation of complement.
Factor H acts as a regulator of the alternative pathway of comple-
ment activation by inhibiting the C3bBb convertase and by being a
cofactor for factor I in inactivating C3b to iC3b [112]. While in DDD the
absence of functional factor H leads to uncontrolled alternative
pathway activation in the ﬂuid phase and deposition of C3b on the
glomerular basement membranes, in aHUS the major problem is an
inability of factor H to recognize C3b on polyanion containing self cell
surfaces. This leads to an indiscriminate attack against endothelial cell
surfaces and against blood cells including platelets. The consequences
include thrombotic microangiopathy, hemolytic anemia and pro-
gressive damage in kidneys. In about 50% of cases, unless treated, the
disease leads to end-stage renal failure. Depending on the nature of the
original cause the disease also recurs in transplanted kidneys.
aHUS is currently treated with eculizumab, a humanized mono-
clonal antibody, which prevents the cleavage of C5 to C5a and C5b.
Thus, both the formation of the C5a anaphylatoxin and MAC, which
involves complement proteins C5b-9, are prevented. While comple-
ment-mediated microangiopathy depending on C5 activation is
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prevented, the C3-dependent immunoprotective functions, such as op-
sonisation are preserved. In general, the use of eculizumab results in the
‘cessation of acute hemolysis’, stabilization of platelet counts and im-
provement of renal function. Plasma exchange is used to remove anti-H
autoantibodies [113]. In selected cases a combined liver-kidney trans-
plantation has been used successfully to treat patients with aHUS [114].
The liver transplant has been needed in patients who produced mutant
complement factor H.
8. Concluding remark
Glomerulonephritis comes in many diﬀerent forms indicating the
fact that kidneys have to handle a number of diﬀerent kinds of chal-
lenges. Some forms are rare, but have educated us a lot about the
clinical importance and mechanisms of the complement system acti-
vation and regulation. Luckily, this has improved the diagnostics and
already in some cases led to improved therapy. Circulating harmful
autoantibodies can be removed by plasmapheresis and consequences of
severe terminal pathway activation can be limited by a therapeutic
complement-inhibiting antibody. Successful treatment of the patients
requires further research in the ﬁeld and close collaboration between
the clinicians and researchers with interest and special expertise in the
complement system.
Acknowledgements
This work was supported by the Research Programs Unit, University
of Helsinki, Finland (730483454), Sigrid Juselius Foundation, Finland
(4705080) Helsinki University Hospital Grants (TYH2019311),
Laboratoriolääketieteen Edistämissäätiö, Finland (4706086), an in-
vestigator-initiated grant from Alexion Corp., US (3999915) and by the
Humanitas University, Milan, Italy. We want to dedicate this article to
our friend, late Marco Ricci, a medical student at the Humanitas
University.
References
[1] J. Floege, K. Amann, Primary glomerulonephritides, Lancet 387 (2016)
2036–2048, https://doi.org/10.1016/S0140-6736(16)00272-5.
[2] W. Kern, F. Silva, Z. Laszik, B. Bane, T. Nadasdy, Pitha J in book Atlas of Renal
Pathology, Chapter 2, Classiﬁcation of Renal Diseases and Mechanisms of Renal
Injury, W.B. Saunders Company, 1999, pp. 7–11.
[3] J. Floege, S.J. Barbour, D.C. Cattran, J.J. Hogan, P.H. Nachman, S.C.W. Tang,
J.F.M. Wetzels, M. Cheung, D.C. Wheeler, W.C. Winkelmayer, B.H. Rovin,
Conference Participants. Management and treatment of glomerular diseases (part
1): conclusions from a Kidney Disease: improving Global Outcomes (KDIGO)
Controversies Conference, Kidney Int. 95 (February (2)) (2019) 268–280, https://
doi.org/10.1016/j.kint.2018.10.018.
[4] O. Wirta, J. Mustonen, H. Helin, A. Pasternack, Incidence of biopsy-proven
glomerulonephritis, Nephrol. Dial. Transplant. 23 (January (1)) (2008) 193–200.
[5] W. Couser, R. Johnson, The etiology of glomerulonephritis: roles of infection and
autoimmunity, Kidney Int. 86 (November (5)) (2014) 905–914, https://doi.org/
10.1038/ki.2014.49.
[6] G. Moroni, C. Ponticelli, Rapidly progressive crescentic glomerulonephritis: early
treatment is a must, Autoimmun. Rev. 13 (7) (2014) 723–729, https://doi.org/10.
1016/j.autrev.2014.02.007.
[7] A. McGrogan, C. Franssen, C. de Vries, The incidence of primary glomerulone-
phritis worldwide: a systematic review of the literature, Nephrol. Dial. Transplant.
26 (2) (2011) 414–430 doi.org/10.1093/ndt/gfq665.
[8] F.C. Berthoux, H. Mohey, A. Aﬁani, Natural history of primary IgA nephropathy,
Semin. Nephrol. 28 (January (1)) (2008) 4–9, https://doi.org/10.1016/j.
semnephrol.2007.10.001.
[9] J. Barratt, A.C. Smith, K. Molyneux, J. Feehally, Immunopathogenesis of IgAN,
Semin. Immunopathol. 29 (November (4)) (2007) 427–443.
[10] D.V. Rizk, N. Maillard, B.A. Julian, B. Knoppova, T.J. Green, J. Novak, R.J. Wyatt,
The emerging role of complement proteins as a target for therapy of IgA ne-
phropathy, Front. Immunol. (March (10)) (2019) 504, https://doi.org/10.3389/
ﬁmmu.2019.00504.
[11] S. Yeo, C. Cheung, J. Barratt, New insights into the pathogenesis of IgA nephro-
pathy, Pediatr. Nephrol. 33 (5) (2018) 763–777.
[12] R. Magistroni, V.D. D’Agati, G.B. Appel, K. Kiryluk, New developments in the
genetics, pathogenesis, and therapy of IgA nephropathy, Kidney Int. 88 (November
(5)) (2015) 974–989, https://doi.org/10.1038/ki.2015.252.
[13] F. Scolari, A. Amoroso, S. Savoldi, G. Mazzola, E. Prati, B. Valzorio, B.F. Viola,
B. Nicola, E. Movilli, M. Sandrini, M. Campanini, R. Maiorca, Familial clustering of
IgA nephropathy: further evidence in an Italian population, Am. J. Kidney Dis. 33
(May (5)) (1999) 857–865.
[14] A.G. Gharavi, Z. Moldoveanu, R.J. Wyatt, C.V. Barker, S.Y. Woodford, R.P. Lifton,
J. Mestecky, J. Novak, B.A. Julian, Aberrant IgA1 glycosylation is inherited in
familial and sporadic IgA nephropathy, J. Am. Soc. Nephrol. 19 (May (5)) (2008)
1008–1014, https://doi.org/10.1681/ASN.2007091052.
[15] J.C. Rodrigues, M. Haas, Reich HN. IgA Nephropathy, Clin. J. Am. Soc. Nephrol.
12 (4) (2017) 677–686, https://doi.org/10.2215/CJN.07420716.
[16] H.T. Cook, Interpretation of renal biopsies in IgA nephropathy, in: Y. Tomino
(Ed.), IgA Nephropathy Today. Contrib Nephrol, Vol. 157 Karger, Basel, 2007, pp.
44–49, , https://doi.org/10.1159/000102287.
[17] J. Varis, I. Rantala, A. Pasternack, H. Oksa, M. Jantti, E.S. Paunu, et al.,
Immunoglobulin and complement deposition in glomeruli of 756 subjects who had
committed suicide or met with a violent death, J. Clin. Pathol. 46 (1993) 607–610.
[18] K. Suzuki, K. Honda, K. Tanabe, H. Toma, H. Nihei, Y. Yamaguchi, Incidence of
latent mesangial IgA deposition in renal allograft donors in Japan, Kidney Int. 63
(2003) 2286–2294, https://doi.org/10.1046/j.1523-1755.63.6s.2.x.
[19] A. Tortajada, E. Gutierrez, M.C. Pickering, M. Praga Terente, N. Medjeral-Thomas,
The role of complement in IgA nephropathy, Mol. Immunol. 24 (July (114))
(2019) 123–132, https://doi.org/10.1016/j.molimm.2019.07.017.
[20] H. Komatsu, S. Fujimoto, S. Hara, Y. Sato, K. Yamada, T. Eto, Relationship between
serum IgA/C3 ratio and progression of IgA nephropathy, Intern. Med. 43
(November (11)) (2004) 1023–1028.
[21] K. Onda, H. Ohi, M. Tamano, I. Ohsawa, M. Wakabayashi, S. Horikoshi, T. Fujita,
Y. Tomino, Hypercomplementemia in adult patients with IgA nephropathy, J. Clin.
Lab. Anal. 21 (2) (2007) 77–84.
[22] Y. Kawasaki, R. Maeda, S. Ohara, K. Suyama, M. Hosoya, Serum IgA/C3 and
glomerular C3 staining predict severity of IgA nephropathy, Pediatr. Int. (Roma)
60 (February (2)) (2018) 162–167, https://doi.org/10.1111/ped.13461.
[23] N.R. Medjeral-Thomas, A. Troldborg, N. Constantinou, H.J. Lomax-Browne,
A.G. Hansen, M. Willicombe, C.D. Pusey, H.T. Cook, S. Thiel, M.C. Pickering,
Progressive IgA nephropathy is associated with low circulating mannan-binding
lectin-associated serine Protease-3 (MASP-3) and increased glomerular factor H-
Related Protein-5 (FHR5) deposition, Kidney Int. Rep. 3 (November (2)) (2017)
426–438, https://doi.org/10.1016/j.ekir.2017.11.015.
Table 1

















Normal levels Deﬁciency of ADAMTS13 due to
mutations in chromosome 9 (in about
10% of cases)
Anti-ADAMTS13









Mutations in CFH, CFI, MCP, C3, FB,
thrombomodulin. Deletion of FHR3-1
found in patients with anti-H





C3GN : decreased levels
of C3








Mutations in CFH, C3 and abnormalities
in CFHR-genes found in some patients
DDD: Anti-C3bBb
C3 Glomerulonephritis:









C3a, Bb and SC5b-9
NA NA Present
K. Kaartinen, et al. Seminars in Immunology 45 (2019) 101331
7
[24] R.J. Wyatt, B.A. Julian, IgA nephropathy, N. Engl. J. Med. 368 (June (25)) (2013)
2402–2414, https://doi.org/10.1056/NEJMra1206793.
[25] N. Maillard, R.J. Wyatt, B.A. Julian, K. Kiryluk, A. Gharavi, V. Fremeaux-Bacchi,
J. Novak, Current understanding of the role of complement in IgA nephropathy, J.
Am. Soc. Nephrol. 26 (July (7)) (2015) 1503–1512, https://doi.org/10.1681/ASN.
2014101000.
[26] T. Moriyama, Clinical and histological features and therapeutic strategies for IgA
nephropathy, Clin. Exp. Nephrol. 23 (September (9)) (2019) 1089–1099, https://
doi.org/10.1007/s10157-019-01735-4.
[27] A. Audemard-Verger, E. Pillebout, L. Guillevin, E. Thervet, B. Terrier, IgA vascu-
litis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects,
Autoimmun. Rev. 14 (July (7)) (2015) 579–585, https://doi.org/10.1016/j.
autrev.2015.02.003.
[28] M.K. Saha, B.A. Julian, J. Novak, D.V. Rizk, Secondary IgA nephropathy, Kidney
Int. 94 (October (4)) (2018) 674–681, https://doi.org/10.1016/j.kint.2018.02.
030.
[29] O. Hotta, T. Furuta, S. Chiba, S. Tomioka, Y. Taguma, Regression of IgA nephro-
pathy: a repeat biopsy study, Am. J. Kidney Dis. 39 (March (3)) (2002) 493–502.
[30] C.L. Harris, R.B. Pouw, D. Kavanagh, R. Sun, D. Ricklin, Developments in anti-
complement therapy; from disease to clinical trial, Mol. Immunol. 102 (October)
(2018) 89–119, https://doi.org/10.1016/j.molimm.2018.06.008.
[31] H. Trimarchi, J. Barratt, D.C. Cattran, H.T. Cook, R. Coppo, M. Haas, Z.H. Liu,
I.S. Roberts, Y. Yuzawa, H. Zhang, J. Feehally, IgAN classiﬁcation working group
of the international IgA nephropathy network and the renal pathology society;
conference participants. Oxford classiﬁcation of IgA nephropathy 2016: an update
from the IgA nephropathy classiﬁcation working group, Kidney Int. 91 (May (5))
(2017) 1014–1021, https://doi.org/10.1016/j.kint.2017.02.003.
[32] S.J. Barbour, R. Coppo, H. Zhang, Z.H. Liu, Y. Suzuki, K. Matsuzaki, R. Katafuchi,
L. Er, G. Espino-Hernandez, S.J. Kim, H.N. Reich, J. Feehally, D.C. Cattran,
International IgA nephropathy network. Evaluating a new international risk-pre-
diction tool in IgA nephropathy, JAMA Intern. Med. 179 (July (7)) (2019)
942–952, https://doi.org/10.1001/jamainternmed.2019.0600.
[33] G. Moroni, M. Belingheri, G. Frontini, F. Tamborini, Messa P. Immunoglobulin A
Nephropathy. Recurrence After Renal Transplantation, Front. Immunol. 10 (2019)
1332 doi.org/10.3389/ﬁmmu.2019.01332.
[34] S. Sethi, F.C. Fervenza, Membranoproliferative glomerulonephritis–a new look at
an old entity, N. Engl. J. Med. 366 (1119) (2012), https://doi.org/10.1056/
NEJMra1108178.
[35] N. Masani, K. Jhaveri, S. Fishbane, Update on membranoproliferative GN, Clin. J.
Am. Soc. Nephrol. 9 (March (3)) (2014) 600–608, https://doi.org/10.2215/CJN.
06410613.
[36] B. Alchi, D. Jayne, Membranoproliferative glomerulonephritis, Pediatr. Nephrol.
25 (August (8)) (2010) 1409–1418, https://doi.org/10.1007/s00467-009-1322-7.
[37] F. Fakhouri, V. Fremeaux-Bacchi, L.H. Noel, L.H. Noël, H.T. Cook, Pickering MC
C3 glomerulopathy: a new classiﬁcation, Nat. Rev. Nephrol. 6 (2010) 494–499.
[38] M.C. Pickering, V.D. D’Agati, C.M. Nester, R.J. Smith, M. Haas, G.B. Appel,
C.E. Alpers, I.M. Bajema, C. Bedrosian, M. Braun, M. Doyle, F. Fakhouri,
F.C. Fervenza, A.B. Fogo, V. Frémeaux-Bacchi, D.P. Gale, E. Goicoechea de Jorge,
G. Griﬃn, C.L. Harris, V.M. Holers, S. Johnson, P.J. Lavin, N. Medjeral-Thomas,
B. Paul Morgan, C.C. Nast, L.H. Noel, D.K. Peters, S. Rodríguez de Córdoba,
A. Servais, S. Sethi, W.C. Song, P. Tamburini, J.M. Thurman, M. Zavros, H.T. Cook,
C3 glomerulopathy: consensus report, Kidney Int. 84 (December (6)) (2013)
1079–1089, https://doi.org/10.1038/ki.2013.377.
[39] H.T. Cook, M.C. Pickering, Histopathology of MPGN and C3 glomerulopathies,
Nat. Rev. Nephrol. 11 (January (1)) (2015) 14–22, https://doi.org/10.1038/
nrneph.2014.217.
[40] R.J.H. Smith, G.B. Appel, A.M. Blom, H.T. Cook, V.D. D’Agati, F. Fakhouri,
V. Fremeaux-Bacchi, M. Józsi, D. Kavanagh, J.D. Lambris, M. Noris,
M.C. Pickering, G. Remuzzi, S.R. de Córdoba, S. Sethi, J. Van der Vlag, P.F. Zipfel,
C.M. Nester, C3 glomerulopathy - understanding a rare complement-driven renal
disease, Nat. Rev. Nephrol. 15 (March (3)) (2019) 129–143, https://doi.org/10.
1038/s41581-018-0107-2.
[41] L. Zand, A. Kettah, F.C. Fervenza, R.J. Smith, S. Nasr, Y. Zhang, J.A. Vrana,
N. Leung, L.D. Cornell, S. Sethi, C3 glomerulonephritis associated with monoclonal
gammopathy, Am J Kid Dis 2013 62 (3) (2013) 506–514.
[42] N. Leung, F. Bridoux, V. Batuman, A. Chaidos, P. Cockwell, V.D. D’Agati,
A. Dispenzieri, F.C. Fervenza, J.P. Fermand, S. Gibbs, J.D. Gillmore, G.A. Herrera,
A. Jaccard, D. Jevremovic, E. Kastritis, V. Kukreti, R.A. Kyle, H.J. Lachmann,
C.P. Larsen, H. Ludwig, G.S. Markowitz, G. Merlini, P. Mollee, M.M. Picken,
V.S. Rajkumar, V. Royal, P.W. Sanders, S. Sethi, C.P. Venner, P.M. Voorhees,
A.D. Wechalekar, B.M. Weiss, S.H. Nasr, The evaluation of monoclonal gammo-
pathy of renal signiﬁcance: a consensus report of the International Kidney and
Monoclonal Gammopathy Research Group, Nat. Rev. Nephrol. 15 (January (1))
(2019) 45–59, https://doi.org/10.1038/s41581-018-0077-4.
[43] G.B. Appel, H.T. Cook, G. Hageman, J.C. Jennette, M. Kashgarian, M. Kirschﬁnk,
J.D. Lambris, L. Lanning, H.U. Lutz, S. Meri, N.R. Rose, D.J. Salant, S. Sethi,
R.J. Smith, W. Smoyer, H.F. Tully, S.P. Tully, P. Walker, M. Welsh, R. Würzner,
P.F. Zipfel, Membranoproliferative glomerulonephritis type II (dense deposit dis-
ease): an update, J. Am. Soc. Nephrol. 16 (May (5)) (2005) 1392–1403.
[44] S. Meri, V. Koistinen, A. Miettinen, T. Törnroth, I.J. Seppälä, Activation of the
alternative pathway of complement by monoclonal lambda light chains in mem-
branoproliferative glomerulonephritis, J. Exp. Med. 175 (4) (1992) 939–950.
[45] P. Iatropoulos, M. Noris, C. Mele, R. Piras, E. Valoti, E. Bresin, M. Curreri,
E. Mondo, A. Zito, S. Gamba, S. Bettoni, L. Murer, V. Fremeaux-Bacchi,
M. Vivarelli, F. Emma, E. Daina, G. Remuzzi, Complement gene variants determine
the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict
long-term renal outcome, Mol. Immunol. 71 (March) (2016) 131–142, https://doi.
org/10.1016/j.molimm.2016.01.010.
[46] A. Servais, L.H. Noël, V. Frémeaux-Bacchi, P. Lesavre, C3 glomerulopathy,
Contrib. Nephrol. 181 (2013) 185–193, https://doi.org/10.1159/000348654.
[47] F. Corvillo, M. Okrój, P. Nozal, M. Melgosa, P. Sánchez-Corral, M. López-Trascasa,
Nephritic Factors: An Overview of Classiﬁcation, Diagnostic Tools and Clinical
Associations, Front. Immunol. 24 (April (10)) (2019) 886, https://doi.org/10.
3389/ﬁmmu.2019.00886.
[48] Y. Zhang, N.C. Meyer, F.C. Fervenza, W. Lau, A. Keenan, G. Cara-Fuentes, D. Shao,
A. Akber, V. Fremeaux-Bacchi, S. Sethi, C.M. Nester, R.J.H. Smith, C4 nephritic
factors in C3 glomerulopathy: a case series, Am. J. Kidney Dis. 70 (December (6))
(2017) 834–843, https://doi.org/10.1053/j.ajkd.2017.07.004.
[49] C. Blanc, S.K. Togarsimalemath, S. Chauvet, M. Le Quintrec, B. Moulin,
M. Buchler, T.S. Jokiranta, L.T. Roumenina, V. Fremeaux-Bacchi, M.A. Dragon-
Durey, Anti-factor H autoantibodies in C3 glomerulopathies and in atypical he-
molytic uremic syndrome: one target, two diseases, J. Immunol. 194 (June (11))
(2015) 5129–5138, https://doi.org/10.4049/jimmunol.1402770.
[50] T.H. Goodship, H.T. Cook, F. Fakhouri, F.C. Fervenza, V. Frémeaux-Bacchi,
D. Kavanagh, C.M. Nester, M. Noris, M.C. Pickering, S. Rodríguez de Córdoba,
L.T. Roumenina, S. Sethi, R.J. Smith, Conference participants. Atypical hemolytic
uremic syndrome and C3 glomerulopathy: conclusions from a "kidney disease:
improving global outcomes" (KDIGO) controversies conference, Kidney Int. 91
(March (3)) (2017) 539–551, https://doi.org/10.1016/j.kint.2016.10.005.
[51] A. Servais, L.H. Noël, L.T. Roumenina, M. Le Quintrec, S. Ngo, M.A. Dragon-Durey,
M.A. Macher, J. Zuber, A. Karras, F. Provot, B. Moulin, J.P. Grünfeld, P. Niaudet,
P. Lesavre, V. Frémeaux-Bacchi, Acquired and genetic complement abnormalities
play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney
Int. 82 (August (4)) (2012) 454–464, https://doi.org/10.1038/ki.2012.63.
[52] W. Zhao, Y. Ding, J. Lu, T. Zhang, D. Chen, H. Zhang, C. Zeng, Z. Liu, H. Chen,
Genetic analysis of the complement pathway in C3 glomerulopathy, Nephrol. Dial.
Transplant. (March) (2018), https://doi.org/10.1093/ndt/gfy033.
[53] T.S. Jokiranta, A. Salomon, M.K. Pangburn, P.F. Zipfel, S. Meri, Nephritogenic
lambda light chain dimer: a unique human miniautoantibody against complement
factor H, J. Immunol. 163 (8) (1999) 4590–4596.
[54] F. Bridoux, N. Leung, C.A. Hutchison, G. Touchard, S. Sethi, J.P. Fermand,
M.M. Picken, G.A. Herrera, E. Kastritis, G. Merlini, M. Roussel, F.C. Fervenza,
A. Dispenzieri, R.A. Kyle, S.H. Nasr, International Kidney and Monoclonal
Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal
signiﬁcance, Kidney Int. 87 (April (4)) (2015) 698–711, https://doi.org/10.1038/
ki.2014.408.
[55] H.T. Cook, C3 glomerulopathy, F1000Res. 6 (March) (2017) 248, https://doi.org/
10.12688/f1000research.10364.1. eCollection 2017.
[56] J. Hou, G.S. Markowitz, A.S. Bomback, G.B. Appel, L.C. Herlitz, M. Barry Stokes,
V.D. D’Agati, Toward a working deﬁnition of C3 glomerulopathy by immuno-
ﬂuorescence, Kidney Int. 85 (February (2)) (2014) 450–456, https://doi.org/10.
1038/ki.2013.340.
[57] C.P. Larsen, N.C. Messias, P.D. Walker, M.E. Fidler, L.D. Cornell, L.H. Hernandez,
M.P. Alexander, S. Sethi, S.H. Nasr, Membranoproliferative glomerulonephritis
with masked monotypic immunoglobulin deposits, Kidney Int. 88 (October (4))
(2015) 867–873, https://doi.org/10.1038/ki.2015.195.
[58] B. Rovin, D. Caster, D. Cattran, K. Gibson, J. Hogan, M. Moeller, D. Roccatello,
M. Cheung, D. Wheeler, W. Winkelmayer, J. Floege, Management and treatment of
glomerular diseases (part 2): conclusions from a Kidney Disease: improving Global
Outcomes (KDIGO) Controversies Conference, Kidney Int. 95 (2019) 281–295,
https://doi.org/10.1016/j.kint.2018.11.008.
[59] B. Martín, R.J. Smith, C3 glomerulopathy, in: M.P. Adam, H.H. Ardinger,
R.A. Pagon, S.E. Wallace, L.J.H. Bean, K. Stephens, A. Amemiya (Eds.),
GeneReviews® [Internet], Seattle (WA): University of Washington, Seattle, 2007,
pp. 1993–2019 Jul 20 [updated 2018 Apr 5].
[60] D.K. Peters, J.A. Charlesworth, J.G. Sissons, D.G. Williams, J.M. Boulton-Jones,
D.J. Evans, O. Kourilsky, L. Morel-Maroger, Mesangiocapillary nephritis, partial
lipodystrophy and hypocomplementaemia, Lancet 2 (1973) 535–538.
[61] J.G.P. Sissons, R.J. West, J. Fallows, D.G. Williams, B.J. Boucher, N. Amos, et al.,
The complement abnor- malities of lipodystrophy, N. Engl. J. Med. 294 (1976)
461–465.
[62] P.W. Mathieson, R. Wurzner, D.B.G. Oliveira, P.J. Lachmann, D.K. Peters,
Complement-mediated adipo- cyte lysis by nephritic factor, J. Exp. Med. 177
(1993) 1827–1831.
[63] B.S. Rosen, K.S. Cook, J. Yaglom, D.L. Groves, J.E. Volanakis, D. Damm, T. White,
B.M. Spiegelman, Adipsin and complement factor D activity: an immune-related
defect in obesity, Science 244 (1989) 1483–1487.
[64] Z.D. Békássy, A.C. Kristoﬀersson, J. Rebetz, R. Tati, A.I. Olin, D. Karpman,
Aliskiren inhibits renin-mediated complement activation, Kidney Int. 94 (October
(4)) (2018) 689–700, https://doi.org/10.1016/j.kint.2018.04.004.
[65] V. Master Sankar Raj, R. Gordillo, D.H. Chand, Overview of C3 Glomerulopathy.
Front Pediatr 4 (45) (2016) 45, https://doi.org/10.3389/fped.2016.00045.
[66] J.A. McCaughan, D.M. O’Rourke, A.E. Courtney, Recurrent dense deposit disease
after renal transplantation: an emerging role for complementary therapies, Am. J.
Transplant. 12 (April (4)) (2012) 1046–1051.
[67] S.H. Nasr, A.M. Valeri, G.B. Appel, J. Sherwinter, M.B. Stokes, S.M. Said,
G.S. Markowitz, V.D. D’Agati, Dense deposit disease: clinicopathologic study of 32
pediatric and adult patients, Clin. J. Am. Soc. Nephrol. 4 (January (1)) (2009)
22–32, https://doi.org/10.2215/CJN.03480708.
[68] C. Rabasco, T. Cavero, E. Román, J. Rojas-Rivera, T. Olea, M. Espinosa, V. Cabello,
G. Fernández-Juarez, F. González, A. Ávila, J.M. Baltar, M. Díaz, R. Alegre,
S. Elías, M. Antón, M.A. Frutos, A. Pobes, M. Blasco, F. Martín, C. Bernis,
K. Kaartinen, et al. Seminars in Immunology 45 (2019) 101331
8
M. Macías, S. Barroso, A. de Lorenzo, G. Ariceta, M. López-Mendoza, B. Rivas,
K. López-Revuelta, J.M. Campistol, S. Mendizábal, S.R. de Córdoba, M. Praga,
Eﬀectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney Int.
(July) (2015), https://doi.org/10.1038/ki.2015.227.
[69] M. Noris, M. Galbusera, S. Gastoldi, P. Macor, F. Banterla, E. Bresin, C. Tripodo,
S. Bettoni, R. Donadelli, E. Valoti, F. Tedesco, A. Amore, R. Coppo, P. Ruggenenti,
E. Gotti, G. Remuzzi, Dynamics of complement activation in aHUS and how to
monitor eculizumab therapy, Blood 124 (September (11)) (2014) 1715–1726,
https://doi.org/10.1182/blood-2014-02-558296.
[70] S. Gurkan, B. Fyfe, L. Weiss, X. Xiao, Y. Zhang, R.J. Smith, Eculizumab and re-
current C3 glomerulonephritis, Pediatr. Nephrol. 28 (October (10)) (2013)
1975–1981, https://doi.org/10.1007/s00467-013-2503-y.
[71] K. Kaartinen, L. Martola, A. Räisänen-Sokolowski, S. Meri, Recurrent allograft C3
glomerulonephritis and unsuccessful eculizumab treatment, Clin. Immunol. 187
(February) (2018) 104–106, https://doi.org/10.1016/j.clim.2017.10.013.
[72] Y. Zhang, C.M. Nester, D.G. Holanda, H.C. Marsh, R.A. Hammond, L.J. Thomas,
N.C. Meyer, L.G. Hunsicker, S. Sethi, R.J.H. Smith, Soluble CR1 therapy improves
complement regulation in C3 glomerulopathy, J Am Soc Nephrol 2013 24 (2013)
1820–1829.
[73] Y. Zhang, D. Shao, D. Ricklin, B.M. Hilkin, C.M. Nester, J.D. Lambris, R.J.H. Smith,
Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glo-
merulopathy, Immunobiol 2015 220 (8) (2015) 993–998.
[74] I.E. Lloyd, A. Gallan, H.K. Huston, K.L. Raphael, D.V. Miller, M.P. Revelo,
M.A. Khalighi, C3 glomerulopathy in adults: a distinct patient subset showing
frequent association with monoclonal gammopathy and poor renal outcome, Clin.
Kidney J. 9 (December (6)) (2016) 794–799.
[75] S.S. Motwani, L. Herlitz, D. Monga, K.D. Jhaveri, A.Q. Lam, Paraprotein-related
kidney disease: glomerular diseases associated with paraproteinemias, Clin. J. Am.
Soc. Nephrol. 11 (December (12)) (2016) 2260–2272 Epub 2016 Aug 15.
[76] P.F. Zipfel, T.S. Jokiranta, J. Hellwage, V. Koistinen, S. Meri, The factor H protein
family, Immunopharmacology. 42 (May (1-3)) (1999) 53–60.
[77] D. Hourcade, V.M. Holers, J.P. Atkinson, The regulators of complement activation
(RCA) gene cluster, Adv. Immunol. 45 (1989) 381–416.
[78] J.P. Venables, L. Strain, D. Routledge, D. Bourn, H.M. Powell, P. Warwicker,
M.L. Diaz-Torres, A. Sampson, P. Mead, M. Webb, Y. Pirson, M.S. Jackson,
A. Hughes, K.M. Wood, J.A. Goodship, T.H. Goodship, A typical haemolytic ur-
aemic syndrome associated with a hybrid complement gene, PLoS Med. 3 (October
(10)) (2006) e431.
[79] N. Medjeral-Thomas, T.H. Malik, M.P. Patel, T. Toth, H.T. Cook, C. Tomson,
M.C. Pickering, A novel CFHR5 fusion protein causes C3 glomerulopathy in a fa-
mily without Cypriot ancestry, Kidney Int. 85 (April (4)) (2014) 933–937, https://
doi.org/10.1038/ki.2013.348 Epub 2013 Sep 25.
[80] R.C. Challis, G.S. Araujo, E.K. Wong, H.E. Anderson, A. Awan, A.M. Dorman,
M. Waldron, V. Wilson, V. Brocklebank, L. Strain, B.P. Morgan, C.L. Harris,
K.J. Marchbank, T.H. Goodship, D. Kavanagh, A de novo deletion in the regulators
of complement activation cluster producing a hybrid complement factor H/
Complement factor H-Related 3 gene in atypical hemolytic uremic syndrome, J.
Am. Soc. Nephrol. 27 (June (6)) (2016) 1617–1624, https://doi.org/10.1681/
ASN.2015010100.
[81] E. Goicoechea de Jorge, J.J. Caesar, T.H. Malik, M. Patel, M. Colledge, S. Johnson,
S. Hakobyan, B.P. Morgan, C.L. Harris, M.C. Pickering, S.M. Lea, Dimerization of
complement factor H-related proteins modulates complement activation in vivo,
Proc Natl Acad Sci U S A. 110 (March (12)) (2013) 4685–4690, https://doi.org/
10.1073/pnas.1219260110.
[82] M. Närkiö-Mäkelä, J. Hellwage, O. Tahkokallio, S. Meri, Complement-regulator
factor H and related proteins in otitis media with eﬀusion, Clin. Immunol. 100
(July (1)) (2001) 118–126.
[83] S.K. Togarsimalemath, S.K. Sethi, R. Duggal, M. Le Quintrec, P. Jha, R. Daniel,
F. Gonnet, S. Bansal, L.T. Roumenina, V. Fremeaux-Bacchi, V. Kher, M.A. Dragon-
Durey, A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomer-
ulopathy, Kidney Int. 92 (October (4)) (2017) 876–887, https://doi.org/10.1016/
j.kint.2017.04.025.
[84] M. Józsi, C. Licht, S. Strobel, S.L. Zipfel, H. Richter, S. Heinen, P.F. Zipfel,
C. Skerka, Factor H autoantibodies in atypical hemolytic uremic syndrome cor-
relate with CFHR1/CFHR3 deﬁciency, Blood. 111 (February (3)) (2008)
1512–1514.
[85] M.A. Durey, A. Sinha, S.K. Togarsimalemath, A. Bagga, Anti-complement-factor H-
associated glomerulopathies, Nat. Rev. Nephrol. 12 (September (9)) (2016)
563–578, https://doi.org/10.1038/nrneph.2016.99.
[86] A. Bhattacharjee, S. Reuter, E. Trojnár, R. Kolodziejczyk, H. Seeberger,
S. Hyvärinen, B. Uzonyi, Á Szilágyi, Z. Prohászka, A. Goldman, M. Józsi,
T.S. Jokiranta, The major autoantibody epitope on factor H in atypical hemolytic
uremic syndrome is structurally diﬀerent from its homologous site in factor H-
related protein 1, supporting a novel model for induction of autoimmunity in this
disease, J. Biol. Chem. 290 (April (15)) (2015) 9500–9510, https://doi.org/10.
1074/jbc.M114.630871.
[87] P. Nozal, M.E. Bernabéu-Herrero, B. Uzonyi, Á Szilágyi, S. Hyvärinen,
Z. Prohászka, T.S. Jokiranta, P. Sánchez-Corral, M. López-Trascasa, M. Józsi,
Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor
H autoantibodies in atypical hemolytic uremic syndrome, Mol. Immunol. 70
(February) (2016) 47–55, https://doi.org/10.1016/j.molimm.2015.12.005.
[88] M.A. Khalighi, S. Wang, K.J. Henriksen, M. Bock, M. Keswani, S.M. Meehan,
A. Chang, Revisiting post-infectious glomerulonephritis in the emerging era of C3
glomerulopathy, Clin. Kidney J. 9 (June (3)) (2016) 397–402, https://doi.org/10.
1093/ckj/sfw032.
[89] S.H. Nasr, G.S. Markowitz, M.B. Stokes, S.M. Said, A.M. Valeri, D.’Agati VD, Acute
postinfectious glomerulonephritis in the modern era: experience with 86 adults
and review of the literature, Bull. Sch. Med. Md 87 (January (1)) (2008) 21–32,
https://doi.org/10.1097/md.0b013e318161b0fc.
[90] N. Kambham, Postinfectious glomerulonephritis, Adv. Anat. Pathol. 19
(September (5)) (2012) 338–347, https://doi.org/10.1097/PAP.
0b013e31826663d9.
[91] B. Al-Ghaithi, R. Chanchlani, M. Riedl, P. Thorner, C. Licht, C3 Glomerulopathy
and post-infectious glomerulonephritis deﬁne a disease spectrum, Pediatr.
Nephrol. 31 (November (11)) (2016) 2079–2086, https://doi.org/10.1007/
s00467-015-3311-3.
[92] S. Sethi, F.C. Fervenza, Y. Zhang, L. Zand, N.C. Meyer, N. Borsa, S.H. Nasr,
R.J. Smith, Atypical postinfectious glomerulonephritis is associated with ab-
normalities in the alternative pathway of complement, Kidney Int. 83 (February
(2)) (2013) 293–299, https://doi.org/10.1038/ki.2012.384.
[93] G. Sandhu, A. Bansal, A. Ranade, J. Jones, S. Cortell, G.S. Markowitz, C3 glo-
merulopathy masquerading as acute postinfectious glomerulonephritis, Am. J.
Kidney Dis. 60 (December (6)) (2012) 1039–1043, https://doi.org/10.1053/j.
ajkd.2012.04.032.
[94] K.A. Vernon, E. Goicoechea de Jorge, A.E. Hall, V. Fremeaux-Bacchi, T.J. Aitman,
H.T. Cook, R. Hangartner, A. Koziell, M.C. Pickering, Acute presentation and
persistent glomerulonephritis following streptococcal infection in a patient with
heterozygous complement factor H-related protein 5 deﬁciency, Am. J. Kidney
Dis. 60 (July (1)) (2012) 121–125, https://doi.org/10.1053/j.ajkd.2012.02.329.
[95] M.N. Rheault, S.E. Wenderfer, Evolving epidemiology of pediatric glomerular
disease, Clin. J. Am. Soc. Nephrol. 6 (July (7)) (2018) 977–978, https://doi.org/
10.2215/CJN.06220518.
[96] W. Couser, Primary membranous nephropathy, Clin. J. Am. Soc. Nephrol. 12 (6)
(2017) 983–997.
[97] L.H. Beck Jr., R.G. Bonegio, G. Lambeau, D.M. Beck, D.W. Powell, T.D. Cummins,
J.B. Klein, D.J. Salant, M-type phospholipase A2 receptor as target antigen in
idiopathic membranous nephropathy, N. Engl. J. Med. 361 (July (1)) (2009)
11–21, https://doi.org/10.1056/NEJMoa0810457.
[98] N.M. Tomas, L.H. Beck Jr, C. Meyer-Schwesinger, B. Seitz-Polski, H. Ma,
G. Zahner, G. Dolla, E. Hoxha, U. Helmchen, A.S. Dabert-Gay, D. Debayle,
M. Merchant, J. Klein, D.J. Salant, R.A.K. Stahl, G. Lambeau, Thrombospondin
type-1 domain-containing 7A in idiopathic membranous nephropathy, N. Engl. J.
Med. 371 (December (24)) (2014) 2277–2287, https://doi.org/10.1056/
NEJMoa1409354.
[99] A. De Vriese, R.J. Glassock, K. Nath, S. Sethi, F. Fervenza, A proposal for a ser-
ology-based approach to membranous nephropathy, J. Am. Soc. Nephrol. 28
(February (2)) (2017) 421–430, https://doi.org/10.1681/ASN.2016070776.
[100] H. Ma, D. Sandor, L. Beck Jr., The role of complement in membranous nephro-
pathy, Semin. Nephrol. 33 (November (6)) (2013) 531–542, https://doi.org/10.
1016/j.semnephrol.2013.08.004.
[101] M.F. Zhang, J. Huang, Y.M. Zhang, Z. Qu, X. Wang, F. Wang, L.Q. Meng,
X.Y. Cheng, Z. Cui, G. Liu, M.H. Zhao, Complement activation products in the
circulation and urine of primary membranous nephropathy, BMC Nephrol. 20
(August (1)) (2019) 313, https://doi.org/10.1186/s12882-019-1509-5.
[102] T.S. Jokiranta, P.F. Zipfel, V. Fremeaux-Bacchi, C.M. Taylor, T.J. Goodship,
M. Noris, Where next with atypical hemolytic uremic syndrome? Mol. Immunol.
44 (September (16)) (2007) 3889–3900.
[103] M. Noris, F. Mescia, G. Remuzzi, STEC-HUS, atypical HUS and TTP are all diseases
of complement activation, Nat. Rev. Nephrol. 8 (November (11)) (2012) 622–633,
https://doi.org/10.1038/nrneph.2012.195.
[104] D. Karpman, S. Loos, R. Tati, I. Arvidsson, Haemolytic uraemic syndrome, J.
Intern. Med. 281 (February (2)) (2017) 123–148, https://doi.org/10.1111/joim.
12546.
[105] M.A. Dragon-Durey, C. Loirat, S. Cloarec, M.A. Macher, J. Blouin, H. Nivet,
L. Weiss, W.H. Fridman, V. Frémeaux-Bacchi, Anti-Factor H autoantibodies asso-
ciated with atypical hemolytic uremic syndrome, J. Am. Soc. Nephrol. 16
(February (2)) (2005) 555–563.
[106] P. Warwicker, T.H. Goodship, R.L. Donne, Y. Pirson, A. Nicholls, R.M. Ward,
P. Turnpenny, J.A. Goodship, Genetic studies into inherited and sporadic hemo-
lytic uremic syndrome, Kidney Int. 53 (April (4)) (1998) 836–844.
[107] C.M. Nester, T. Barbour, S.R. de Cordoba, M.A. Dragon-Durey, V. Fremeaux-
Bacchi, T.H. Goodship, D. Kavanagh, M. Noris, M. Pickering, P. Sanchez-Corral,
C. Skerka, P. Zipfel, R.J. Smith, Atypical aHUS: state of the art, Mol. Immunol. 67
(September (1)) (2015) 31–42, https://doi.org/10.1016/j.molimm.2015.03.246.
[108] J. Hellwage, T.S. Jokiranta, M.A. Friese, T.U. Wolk, E. Kampen, P.F. Zipfel,
S. Meri, Complement C3b/C3d and cell surface polyanions are recognized by
overlapping binding sites on the most carboxyl-terminal domain of complement
factor H, J. Immunol. 169 (December (12)) (2002) 6935–6944.
[109] T. Kajander, M.J. Lehtinen, S. Hyvärinen, A. Bhattacharjee, E. Leung,
D.E. Isenman, S. Meri, A. Goldman, T.S. Jokiranta, Dual interaction of factor H
with C3d and glycosaminoglycans in host-nonhost discrimination by complement,
Proc Natl Acad Sci U S A. 108 (February (7)) (2011) 2897–2902, https://doi.org/
10.1073/pnas.1017087108.
[110] B.S. Blaum, J.P. Hannan, A.P. Herbert, D. Kavanagh, D. Uhrín, T. Stehle, Structural
basis for sialic acid-mediated self-recognition by complement factor H, Nat. Chem.
Biol. 11 (January (1)) (2015) 77–82, https://doi.org/10.1038/nchembio.1696.
[111] M.A. Dragon-Durey, V. Frémeaux-Bacchi, Atypical haemolytic uraemic syndrome
and mutations in complement regulator genes, Springer Semin. Immunopathol. 27
(November (3)) (2005) 359–374.
[112] M.A. Dragon-Durey, S.K. Sethi, A. Bagga, C. Blanc, J. Blouin, B. Ranchin,
J.L. André, N. Takagi, H.I. Cheong, P. Hari, M. Le Quintrec, P. Niaudet, C. Loirat,
W.H. Fridman, V. Frémeaux-Bacchi, Clinical features of anti-factor H
K. Kaartinen, et al. Seminars in Immunology 45 (2019) 101331
9
autoantibody-associated hemolytic uremic syndrome, J. Am. Soc. Nephrol. 21
(December (12)) (2010) 2180–2187.
[113] B.S. Kaplan, R.L. Ruebner, J.M. Spinale, L. Copelovitch, Current treatment of
atypical hemolytic uremic syndrome, Intractable Rare Dis. Res. 3 (2) (2014)
34–45.
[114] H. Jalanko, S. Peltonen, A. Koskinen, J. Puntila, H. Isoniemi, C. Holmberg,
A. Pinomäki, E. Armstrong, A. Koivusalo, E. Tukiainen, H. Mäkisalo, J. Saland,
G. Remuzzi, S. de Cordoba, R. Lassila, S. Meri, T.S. Jokiranta, Successful liver-
kidney transplantation in two children with aHUS caused by a mutation in com-
plement factor H, Am. J. Transplant. 8 (1) (2008) 216–221.
K. Kaartinen, et al. Seminars in Immunology 45 (2019) 101331
10
